JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression

MASASHI OKADA, ATSUSHI SATO, KEITA SHIBUYA, ERIKO WATANABE, SHIZUKA SEINO, SHUHEI SUZUKI, MANABU SEINO, YOSHITAKA NARITA, SOICHIRO SHIBUI, TAKAMASA KAYAMA, CHIFUMI KITANAKA
2013 International Journal of Oncology  
While elimination of the cancer stem cell population is increasingly recognized as a key to successful treatment of cancer, the high resistance of cancer stem cells to conventional chemoradiotherapy remains a therapeutic challenge. O 6 -methylguanine DNA methyltransferase (MGMT), which is frequently expressed in cancer stem cells of glioblastoma, has been implicated in their resistance to temozolomide, the first-line chemotherapeutic agent against newly diagnosed glioblastoma. However, much
more » ... . However, much remains unknown about the molecular regulation that underlies MGMT expression and temozolomide resistance of glioblastoma cancer stem cells. Here, we identified JNK as a novel player in the control of MGMT expression and temozolomide resistance of glioblastoma cancer stem cells. We showed that inhibition of JNK, either pharmacologically or by RNA interference, in stem-like glioblastoma cells derived directly from glioblastoma tissues reduces their MGMT expression and temozolomide resistance. Importantly, sensitization of stem-like glioblastoma cells to temozolomide by JNK inhibition was dependent on MGMT expression, implying that JNK controls temozolomide resistance of stem-like glioblastoma cells through MGMT expression. Our findings suggest that concurrent use of JNK inhibitors with temozolomide may be a rational therapeutic approach to effectively target the cancer stem cell population in the treatment of glioblastoma.
doi:10.3892/ijo.2013.2209 pmid:24316756 fatcat:r2b6dkqtvrhj3e6r5iz7ojmlgu